Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 5/20 | 0.49 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.44 |
| ▸ | MEN1 | O00255 | 3/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.43 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
| ▸ | NAMPT | P43490 | 2/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.41 |
| ▸ | BCHE | P06276 | 1/20 | 0.40 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.39 |
| ▸ | CNR1 | P21554 | 1/20 | 0.38 |
| ▸ | CNR2 | P34972 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23149339 | 0.83 | — | — | |
| SCHEMBL5572067 | 0.80 | KMT2A (0.54) | KMT2ALMNANPSR1MEN1CYP2C19 | |
| SCHEMBL3705956 | 0.77 | KMT2A (0.59) | KMT2ALMNANPSR1MEN1CYP2C19 | |
| SCHEMBL24664428 | 0.77 | KMT2A (0.59) | KMT2ALMNANPSR1MEN1CYP2C19 | |
| SCHEMBL1651682 | 0.75 | LMNA (0.61) | KMT2ALMNANPSR1MEN1CYP2C19 | |
| SCHEMBL10272740 | 0.73 | TDP1 (0.62) | KMT2ALMNANPSR1MEN1CYP2C19 | |
| Hydrochloric Acid SCHEMBL10806956 | 0.73 | LMNA (0.59) | KMT2ALMNANPSR1MEN1CYP2C19 | |
| SCHEMBL5238995 | 0.72 | KMT2A (0.54) | KMT2ALMNANPSR1MEN1CYP2C19 | |
| SCHEMBL2760109 | 0.72 | HTT (0.77) | KMT2ALMNANPSR1MEN1HTT | |
| SCHEMBL10818831 | 0.72 | KMT2A (0.55) | KMT2ALMNANPSR1MEN1CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11370808-B2 | Pyrazole compounds and methods for making and using the compounds | RIGEL PHARMACEUTICALS, INC. (US) | 2022-06-28 | — | — | US | disclosed |
| EP-3286181-B1 | PYRAZOLE COMPOUNDS AND METHOD FOR MAKING AND USING THE COMPOUNDS | RIGEL PHARMACEUTICALS INC (US) | 2021-01-27 | — | — | EP | disclosed |
| US-20190153006-A1 | PYRAZOLE COMPOUNDS AND METHODS FOR MAKING AND USING THE COMPOUNDS | RIGEL PHARMACEUTICALS, INC. (US) | 2019-05-23 | — | — | US | disclosed |
| US-10208074-B2 | Pyrazole compounds and method for making and using the compounds | RIGEL PHARMACEUTICALS, INC. (US) | 2019-02-19 | — | — | US | disclosed |
| US-10208075-B2 | Pyrazole compounds and method for making and using the compounds | RIGEL PHARMACEUTICALS, INC. (US) | 2019-02-19 | — | — | US | disclosed |
| US-20180208613-A1 | PYRAZOLE COMPOUNDS AND METHOD FOR MAKING AND USING THE COMPOUNDS | RIGEL PHARMACEUTICALS, INC. (US) | 2018-07-26 | — | — | US | disclosed |
| US-20180208612-A1 | PYRAZOLE COMPOUNDS AND METHOD FOR MAKING AND USING THE COMPOUNDS | RIGEL PHARMACEUTICALS, INC. (US) | 2018-07-26 | — | — | US | disclosed |
| US-9982000-B2 | Pyrazole compounds and method for making and using the compounds | RIGEL PHARMACEUTICALS, INC. (US) | 2018-05-29 | — | — | US | disclosed |
| EP-3286181-A1 | PYRAZOLE COMPOUNDS AND METHOD FOR MAKING AND USING THE COMPOUNDS | Rigel Pharmaceuticals, Inc. (US) | 2018-02-28 | — | — | EP | disclosed |
| WO-2016172560-A1 | PYRAZOLE COMPOUNDS AND METHOD FOR MAKING AND USING THE COMPOUNDS | RIGEL PHARMACEUTICALS, INC. (US) | 2016-10-27 | — | — | WO | disclosed |
| US-20160311839-A1 | PYRAZOLE COMPOUNDS AND METHOD FOR MAKING AND USING THE COMPOUNDS | RIGEL PHARMACEUTICALS, INC. (US) | 2016-10-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11370808-B2 | Pyrazole compounds and methods for making and using the compounds | IRAK3, IRAK1, IRAK2 | KMT2A 1935/4885LMNA 2091/4885NPSR1 4345/4885 |
| US-10208074-B2 | Pyrazole compounds and method for making and using the compounds | IRAK3, IRAK1, IRAK2 | KMT2A 1959/4885LMNA 2059/4885NPSR1 4160/4885 |
| US-20190153006-A1 | PYRAZOLE COMPOUNDS AND METHODS FOR MAKING AND USING THE COMPOUNDS | IRAK3, IRAK1, IRAK2 | KMT2A 1935/4885LMNA 2091/4885NPSR1 4345/4885 |
| US-20180208613-A1 | PYRAZOLE COMPOUNDS AND METHOD FOR MAKING AND USING THE COMPOUNDS | IRAK3, IRAK1, IRAK2 | KMT2A 1959/4885LMNA 2059/4885NPSR1 4160/4885 |
| US-10208075-B2 | Pyrazole compounds and method for making and using the compounds | IRAK3, IRAK1, IRAK2 | KMT2A 1959/4885LMNA 2059/4885NPSR1 4160/4885 |
| US-20180208612-A1 | PYRAZOLE COMPOUNDS AND METHOD FOR MAKING AND USING THE COMPOUNDS | IRAK3, IRAK1, IRAK2 | KMT2A 1959/4885LMNA 2059/4885NPSR1 4160/4885 |
| US-20160311839-A1 | PYRAZOLE COMPOUNDS AND METHOD FOR MAKING AND USING THE COMPOUNDS | IRAK3, IRAK1, IRAK2 | KMT2A 1959/4885LMNA 2059/4885NPSR1 4160/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.